The Short Answer
Halozyme stock (HALO) has a qualitative business verdict that is HALAL, but its current filing-based financial screen FAILS on debt. Halozyme licenses its drug-delivery enzyme technology to pharmaceutical partners in exchange for royalties.
Development and licensing of pharmaceutical drug-delivery technology is generally permissible at the activity level. The March 31, 2026 filing reports debt/assets of 80.24%, liquidity/assets of 11.92% and receivables-plus-cash/assets of 28.75%; the debt screen fails the examined limits.
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-15.
2,144.639 / 2,672.719
318.622 / 2,672.719
767.738 / 2,672.719
1.318 / 376.708
- Financial
- Fails
- Overall
- Fails
Debt/assets is 80.24%, above the examined limit; liquidity/assets is 11.92% and receivables-plus-cash/assets is 28.75%.
- Financial
- Fails
- Overall
- Fails
Debt/assets is 80.24%, above the examined limit; this is not an index-membership claim.
- Financial
- Fails
- Overall
- Fails
Debt/assets is 80.24%, above the examined limit; this is not an official classification.
- Financial
- Not calculated
- Overall
- Fails
A licensed historical market-cap series is not stored; asset-based debt screens already fail.
Business-activity disclosure
Halozyme develops injectable-drug delivery technologies and earns royalties, product sales and collaborative-agreement revenue. Healthcare technology is generally permissible, but the filing does not provide a universal prohibited-revenue numerator for licensing and end uses.
Limitation: No universal prohibited-activity revenue numerator or scholar-specific purification percentage is disclosed.
Purification
Investment and other income is disclosed as a mixed net amount; no fixed purification percentage is inferred.
Inputs, assumptions and primary sources
- Amounts are USD thousands from Halozyme's March 31, 2026 Form 10-Q; this record expresses them in millions-equivalent values.
- Debt is current and non-current long-term debt of $208.743 million and $1,935.896 million; operating leases are excluded.
- Cash is $309.749 million and available-for-sale securities are $8.873 million; accounts receivable and contract assets are $457.989 million.
- Quarterly revenue is $376.708 million and investment and other income, net is $1.318 million, used as a conservative upper bound.
- Drug-delivery licensing and pharmaceutical end uses remain qualitative; no universal prohibited-revenue numerator is disclosed.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Sharia Screening Methodology
Islamic scholars use several criteria to screen stocks:
- Business activity screen: Is the company's primary business halal?
- Debt ratio: Total debt / market cap must be under 33%
- Interest income: Interest income / total revenue must be under 5%
- Haram revenue: Revenue from haram sources must be under 5%
- Receivables ratio: Total receivables / total assets must be under 49–70% (varies by board)
Halozyme's Business Activity
Halozyme generates revenue from:
- ENHANZE royalties: Its recombinant human hyaluronidase enzyme enables subcutaneous delivery of partners' biologic drugs
- Milestone payments: Earned as partner programs advance and launch
- Proprietary products: A smaller specialty-products portfolio
This is a permissible healthcare and pharmaceutical-technology business at the activity level.
Concerns to Be Aware Of
1. Convertible-Note Leverage — The Primary Screen
The filing reports $2,144.639 million of current and non-current long-term debt, or 80.24% of total assets. This exceeds the examined asset-based debt limits; market-cap denominator methods are not calculated here.
2. Interest-Bearing Instruments
Convertible notes are interest-bearing instruments. Investors who object to any conventional-debt issuance should weigh this even where the debt ratio passes the 33% screen.
3. Partner Concentration
Royalty revenue is concentrated in a relatively small set of partner drugs, and a partner-patent or competitive event could affect results. This is a business consideration rather than a Sharia screen concern.
Filing-Based Ratios (March 31, 2026)
Using Halozyme's latest Form 10-Q (USD millions):
- Debt / total assets: 80.24% — above the examined one-third limits
- Cash + securities / total assets: 11.92%
- Receivables + cash / total assets: 28.75%
- Investment and other income upper bound: 0.35% of revenue
Methodology Interpretation
These are ZakatInvest calculations from the cited filing, not claims of current index membership or an official scholar ruling:
- FTSE-style: Debt screen fails at 80.24%.
- MSCI-style: Debt screen fails at 80.24%; this is not an index-membership claim.
- Malaysia-style: Debt screen fails at 80.24%; this is not an official classification.
Bottom Line
Halozyme (HALO) has a generally permissible pharmaceutical-technology business, but its current filing-based debt screen fails. The qualitative business verdict remains HALAL while the quantitative result is not compliant under the examined financial limits; consult the methodology you follow.
For Muslim investors seeking healthcare and biopharma exposure, HALO sits alongside other halal-screened names like Eli Lilly (LLY) and Exelixis (EXEL).
Want to check if another stock is halal? Use our free screener.
Open Halal Checker →